Efficacy of azithromycin in the treatment of cutaneous leishmaniasis
Rev. Soc. Bras. Med. Trop
;
36(1): 65-69, jan.-fev. 2003. tab
Artículo
en Inglés
| LILACS
| ID: lil-332890
ABSTRACT
The present open pilot study was conducted to assess the efficacy of azithromycin for the treatment of patients with cutaneous leishmaniasis in Araçuaí and Varzelândia, MG. Twenty-four patients with less of six months of disease evolution were treated after clinical examination, Montenegro test and a biopsy. The treatment schemes consisted of oral doses of 500 mg per day for 3, 5 and 10 days and of 1000 mg for two days. A clinical control was performed monthly and treatment cycles were repeated when necessary until full reepithelialization of the lesions. On the occasion of the final evaluation, 20 patients had completed the study and 17 of them (85 percent) were cured. The time to obtain a cure was 60 days ifor 6 (30 percent) patients, 90 days for 7 (35 percent), and 120 for 4 (20 percent). The three patients with treatment failure received a pentavalent antimonial for 20 days. No adverse reactions to the medication were observed and a 14 month follow-up did not show recurrence in any patient. These results suggest that azithromycin can be a good therapeutic option for the treatment of cutaneous leishmaniasis caused by Leishmania Viannia brasiliensis
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Leishmaniasis Cutánea
/
Azitromicina
/
Antibacterianos
Tipo de estudio:
Estudios de evaluación
/
Estudio observacional
/
Estudio pronóstico
Límite:
Animales
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
Medicina Tropical
Año:
2003
Tipo del documento:
Artículo
País de afiliación:
Argentina
/
Brasil
Institución/País de afiliación:
Faculdade de Medicina do Triângulo Mineiro/BR
/
Fundacion Huesped/AR
/
Ministério da Saúde/BR
/
Municipal Polyclinic of Araçuaí/BR
/
Universidade Federal de Uberlândia/BR
Similares
MEDLINE
...
LILACS
LIS